Skip to main content

High Blood Pressure

2
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 5 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
1
1
Aliskiren and HCTZPhase 41 trial
AliskirenPhase 21 trial
NadololPHASE_1Small Molecule1 trial
Active Trials
NCT00960245Completed34Est. Jul 1994
NCT00417170Completed48Est. Jul 2010
NCT01056731Completed253Est. Oct 2011
CVRx
CVRxMN - Minneapolis
1 program
BAROSTIM NEO SystemN/A1 trial
Active Trials
NCT01471834Active Not Recruiting40Est. Aug 2026
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Whey ProteinN/A1 trial
Active Trials
NCT00659672Completed35Est. Feb 2009
Eisai
EisaiChina - Liaoning
1 program
BunazosinPHASE_41 trial
Active Trials
NCT00130156Completed93Est. Mar 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozAliskiren and HCTZ
EisaiBunazosin
SandozAliskiren
SandozNadolol
CVRxBAROSTIM NEO System
Human BioSciencesWhey Protein

Clinical Trials (6)

Total enrollment: 503 patients across 6 trials

NCT01056731SandozAliskiren and HCTZ

A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.

Start: Feb 2010Est. completion: Oct 2011253 patients
Phase 4Completed
NCT00130156EisaiBunazosin

Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

Start: Oct 2005Est. completion: Mar 200993 patients
Phase 4Completed
NCT00417170SandozAliskiren

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Start: Oct 2007Est. completion: Jul 201048 patients
Phase 2Completed
NCT00960245SandozNadolol

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

Start: Jul 1994Est. completion: Jul 199434 patients
Phase 1Completed
NCT01471834CVRxBAROSTIM NEO System

Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension

Start: Jun 2011Est. completion: Aug 202640 patients
N/AActive Not Recruiting
NCT00659672Human BioSciencesWhey Protein

Effect of Whey Protein on Blood Pressure

Start: Sep 2008Est. completion: Feb 200935 patients
N/ACompleted

Related Jobs

Associate Director, Marketing - Patient Adherence

Merck & Co.Merck & Co.
USA - Pennsylvania - North Wales (Upper Gwynedd) (Hybrid)
1w ago
$142K - $224K/yr

Associate Director, Marketing - Patient Adherence

Verona PharmaVerona Pharma
USA - Pennsylvania - North Wales (Upper Gwynedd) (Hybrid)
1w ago
$142K - $224K/yr

Senior Principal System Architect - Digital Ecosystem Coronary and Renal Denervation CRDN

MedtronicMedtronic
Galway, County Galway, Ireland (Flexible Work Arrangement)
2w ago

Join Our Talent Community

Gossamer BioGossamer Bio
San Diego, California, United States
5mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.